These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 1688245)

  • 1. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE; Relling MV
    Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of phenotype for dextromethorphan O-demethylation by using polymerase chain reaction in healthy volunteers.
    Zimmermann T; Schlenk R; Pfaff G; Lach P; Wildfeuer A
    Arzneimittelforschung; 1995 Jan; 45(1):41-3. PubMed ID: 7893267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans.
    Funck-Brentano C; Thomas G; Jacqz-Aigrain E; Poirier JM; Simon T; Béréziat G; Jaillon P
    J Pharmacol Exp Ther; 1992 Nov; 263(2):780-6. PubMed ID: 1432700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
    Broly F; Meyer UA
    Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis.
    Hou ZY; Chen CP; Yang WC; Lai MD; Buchert ET; Chung HM; Pickle LW; Woosley RL
    Clin Pharmacol Ther; 1996 Apr; 59(4):411-7. PubMed ID: 8612385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
    Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
    Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
    Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M
    J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
    Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
    DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
    Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
    J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
    Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
    Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Correlation of genetic polymorphism of cytochrome P4502D6 with dextromethorphan oxidative metabolism in Chinese].
    Cai W; Chen B; Tao X; Ling S; Zhang Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2000 Jun; 17(3):181-4. PubMed ID: 10837520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
    Dorado P; Cáceres MC; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
    Biotechniques; 2005 Oct; 39(4):571-4. PubMed ID: 16235570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Xbal 16- plus 9-kilobase DNA restriction fragments identify a mutant allele for debrisoquin hydroxylase: report of a family study.
    Evans WE; Relling MV
    Mol Pharmacol; 1990 May; 37(5):639-42. PubMed ID: 1971090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction.
    Rebsamen MC; Desmeules J; Daali Y; Chiappe A; Diemand A; Rey C; Chabert J; Dayer P; Hochstrasser D; Rossier MF
    Pharmacogenomics J; 2009 Feb; 9(1):34-41. PubMed ID: 18591960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico.
    Sosa-Macías M; Elizondo G; Flores-Pérez C; Flores-Pérez J; Bradley-Alvarez F; Alanis-Bañuelos RE; Lares-Asseff I
    J Clin Pharmacol; 2006 May; 46(5):527-36. PubMed ID: 16638736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotype/genotype relationships for the cytochrome P450 enzyme CYP2D6 in rheumatoid arthritis: influence of drug therapy and disease activity.
    Beyeler C; Daly AK; Armstrong M; Astbury C; Bird HA; Idle JR
    J Rheumatol; 1994 Jun; 21(6):1034-9. PubMed ID: 7932410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.
    Sachse C; Brockmöller J; Bauer S; Roots I
    Am J Hum Genet; 1997 Feb; 60(2):284-95. PubMed ID: 9012401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism.
    Turgeon J; Evans WE; Relling MV; Wilkinson GR; Roden DM
    Br J Clin Pharmacol; 1991 Sep; 32(3):283-8. PubMed ID: 1685663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
    Neafsey P; Ginsberg G; Hattis D; Sonawane B
    J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Debrisoquine polymorphism: novel CYP2D6 gene Bam HI restriction fragment length polymorphism in the Ngawbé Guaymí Indian of Panama.
    Petersen DD; Kong AN; Jorge LF; Nebert DW; Arias TD
    Pharmacogenetics; 1991 Dec; 1(3):136-42. PubMed ID: 1688244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.